|
| Monday, June 26, 2023 |
|
|
Prenetics与全球知名科学家卢煜明教授宣布成立2亿美元合资企业“Insighta” 推出突破性多种癌症早期筛查检测 |
| Prenetics Global Limited ( https://ir.prenetics.com/ )（纳斯达克：PRE ( https://www.nasdaq.com/market-activity/stocks/pre ) ）– 由基因组学驱动的领先健康科学公司 – 与卢煜明教授 ( https://www.cuhk.edu.hk/med/cpy/Research/DennisLo.htm )今天宣布双方达成协议，成立合资企业Insighta。Prenetics的董事会已一致通过这次交易。 more info >> |
|
|
Prenetics與全球知名科學家盧煜明教授宣布成立2億美元合資企業「Insighta」推出突破性多種癌症早期篩查檢測 |
| Prenetics Global Limited ( https://ir.prenetics.com/ )（納斯達克：PRE ( https://www.nasdaq.com/market-activity/stocks/pre ) ）– 由基因組學驅動的領先健康科學公司 – 與盧煜明教授 ( https://www.cuhk.edu.hk/med/cpy/Research/DennisLo.htm ) 今天宣布雙方達成協議，成立合資企業Insighta。Prenetics的董事會已一致通過這次交易。 more info >> |
|
|
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture "Insighta" for Breakthrough Multi-Cancer Early Detection Screening |
| Prenetics Global Limited (NASDAQ: PRE), a leading genomics-driven health sciences company, and Prof. Dennis Lo today announce they have entered into an agreement to establish a joint venture, named Insighta. The board of directors of Prenetics Global Limited has unanimously approved the transaction. more info >> |
|
| Tuesday, March 14, 2023 |
|
|
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology |
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full year ended December 31, 2022.
more info >> |
|
|
Prenetics公布2022年第四季度及全年财务业绩 新业务策略专注于精准肿瘤学 |
| 领先的基因组学和精准肿瘤学公司Prenetics Global Limited（纳斯达克：PRE）（「Prenetics」或「公司」）今日公布截至2022年12月31日止第四季度及全年财务业绩。 more info >> |
|
|
Prenetics公布2022年第四季度及全年財務業績 新業務策略專注於精準腫瘤學 |
| 領先的基因組學和精準腫瘤學公司Prenetics Global Limited（納斯達克：PRE）（「Prenetics」或「公司」）今日公布截至2022年12月31日止第四季度及全年財務業績。 more info >> |
|
| Saturday, March 4, 2023 |
|
|
Prenetics宣布成立科學顧問委員會 助力公司腫瘤精準醫療業務布局 |
| 納斯達克上市公司Prenetics Global Limited（NASDAQ: PRE）宣布成立科學顧問委員會（「SAB」）。 more info >> |
|
|
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology |
| Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB') to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics' diagnostic cancer genomics platform. more info >> |
|
| Thursday, January 26, 2023 |
|
|
Cantor Fitzgerald首次覆盖 普瑞健康予“增持”评级 |
| 据悉Cantor Fitzgerald首次覆盖普瑞健康Prenetics Global (PRE.US)并予“增持”评级，目标价为7.00美元。 more info >> |
|
|
Cantor Fitzgerald首次覆蓋 普瑞健康予“增持”評級 |
| 據悉Cantor Fitzgerald首次覆蓋普瑞健康Prenetics Global (PRE.US)並予“增持”評級，目標價為7.00美元。 more info >> |
|
|
|
|
